Most current therapies for alcohol and drug abuse are based on counseling and behavioral modification. These approaches help and are successful for some. To date, the FDA has approved only a handful of medications for alcohol abuse, and the effectiveness of these medications is limited. Dr. Bartlett has established and directs the Preclinical Development Group, which is focused on the translation of basic research discoveries into drugable targets and new treatments for neurological diseases such as addiction, pain, stress, anxiety, and depression. Dr. Bartlett’s research has led to findings that suggest possible links between the neurochemical pathways for alcohol and nicotine dependence and between addiction and compulsive eating.

Lab Members (Preclinical Development Group):
Jade Bito-Onon, Staff Research Associate
Susmita Chatterjee, Ph.D., Postdoctoral Fellow
Allison Feduccia, Ph.D., Postdoctoral Research Fellow
Carolina Haass-Koffler, Postdoctoral Fellow
Andrea Henry, Staff Research Associate
Joan Holgate, Specialist
Rui Li, Research Student
Douglas Mill, Research Student
Mohammed Naeemuddin, Senior Staff Research Associate
Carsten Nielsen, Ph.D., Associate Research Scientist
Nathan Santos, Laboratory Assistant
Jeffrey Simms, Manager of Preclinical Development
Subhashini Srinivasan, Postdoctoral Research Fellow


Selena Bartlett’s publications